Policy & Regulation
Adlon Therapeutics LP announces funding opportunities for research to expand knowledge of ADHD
13 May 2019 -

Biopharmaceutical company Adlon Therapeutics LP, a subsidiary of Purdue Pharma LP, declared on Monday that it will issue a funding opportunity for investigator-initiated research (IIR) studies to contribute to the knowledge and understanding of Attention-Deficit/Hyperactivity Disorder (ADHD).

Adlon said it is dedicated to improving the lives of individuals with ADHD, and will provide support for studies that contribute to a better understating of the condition. Clinical research conducted under Adlon's IIR program will be developed and implemented entirely by researchers in the US, with funding provided by Adlon.

The company added that it will accept research proposals for this funding from interested US-based researchers, from 13 May 2019 through to 14 June 2019.

Applications will be evaluated by Adlon's IIR Review Committee, then a selected set of applicants will be invited to submit a complete study proposal and corresponding budget for evaluation.